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Doripenem and ertapenem have demonstrated efﬁcacy against several NDM-1-producing isolates in vivo, despite having high
MICs. In this study, we sought to further characterize the efﬁcacy proﬁles of humanized regimens of standard (500 mg given ev-
ery 8 h) and high-dose, prolonged infusion of doripenem (2 g given every 8 h, 4-h infusion) and 1 g of ertapenem given intrave-
nously every 24 h and the comparator regimens of ceftazidime at 2 g given every 8 h (2-h infusion), levoﬂoxacin at 500 mg every
24 h, and aztreonam at 2 g every 6 h (1-h infusion) against a wider range of isolates in a murine thigh infection model. An iso-
genic wild-type strain and NDM-1-producing Klebsiella pneumoniae and eight clinical NDM-1-producing members of the fam-
ily Enterobacteriaceae were tested in immunocompetent- and neutropenic-mouse models. The wild-type strain was susceptible
to all of the agents, while the isogenic NDM-1-producing strain was resistant to ceftazidime, doripenem, and ertapenem. Clinical
NDM-1-producing strains were resistant to nearly all ﬁve of the agents (two were susceptible to levoﬂoxacin). In immunocompe-
tent mice, all of the agents produced>1-log10 CFU reductions of the isogenic wild-type and NDM-1-producing strains after 24 h.
Minimal efﬁcacy of ceftazidime, aztreonam, and levoﬂoxacin against the clinical NDM-1-producing strains was observed. How-
ever, despite in vitro resistance,>1-log10 CFU reductions of six of eight clinical strains were achieved with high-dose, prolonged
infusion of doripenem and ertapenem. Slight enhancements of doripenem activity over the standard doses were obtained with
high-dose, prolonged infusion for three of the four isolates tested. Similar efﬁcacy observations were noted in neutropenic mice.
These data suggest that carbapenems are a viable treatment option for infections caused by NDM-1-producing
Enterobacteriaceae.
New Delhi metallo--lactamase (NDM-1) is a novel carbapen-emase that was ﬁrst identiﬁed in a Klebsiella pneumoniae iso-
late in India in 2008 (1). Since then, it has disseminated at a high
rate amongEnterobacteriaceae isolates bothwithin the Indian sub-
continent and worldwide (2–4). The treatment options for infec-
tions caused by NDM-1-producing isolates are extremely limited,
as these enzymes are known to hydrolyze penicillins, cephalospo-
rins, and carbapenems while typically retaining susceptibility to
only colistin and tigecycline (2), neither of which has been shown
to be a dependable option on the basis of in vitro time-kill data
and case reports (5–8). Aztreonam is not readily inactivated by
metallo--lactamases, including NDM-1, and may represent an-
other potential option for therapy (1, 9). However, NDM-1-pro-
ducing strains often coproduce other -lactamases, such as
CTX-M- and CMY-type enzymes, that possess the ability to hy-
drolyze aztreonam, further limiting the utility of all -lactam an-
tibiotics (1). Furthermore, in vivo efﬁcacy data evaluating poten-
tial treatment options for NDM-1-producing isolates are sparse
and clinical experience in treating infections caused by these iso-
lates is limited to case reports.
Unlike in vivo observations with isolates that produce the ser-
ine-carbapenemase KPC, carbapenem monotherapy has demon-
strated reductions of NDM-1-producing bacterial isolates in a
murine thigh infection model, even though the time that the con-
centration of an unbound antibiotic remains above the MIC dur-
ing the dosing interval (ƒTMIC) needed for efﬁcacy was not
achieved for all of the isolates (10, 11). Previouswork by our group
has demonstrated a reduction in bacterial density with human
simulated monotherapy regimens of ertapenem and high-dose,
prolonged infusion of doripenem against an isogenically con-
structed NDM-1-producing strain and four clinical NDM-1-pro-
ducing strains in a murine thigh infection model (10). Since these
results were both surprising and promising, it is essential to vali-
date them with additional in vivo studies before determining the
potential clinical utility of carbapenems for treating infections
caused by NDM-1-producing organisms. A high-dose, prolonged
doripenem infusion regimen (2 g given every 8 h as a 4-h infusion)
was initially evaluated in the previous study for its potential to
achieve the requisite pharmacodynamic target needed for efﬁcacy
against these resistant pathogens. Since considerable efﬁcacy was
observed with this regimen despite in vitro resistance, a standard
dose of doripenem (500 mg given every 8 h) also warrants further
study. Furthermore, only four clinical isolateswere included in the
initial study. Efﬁcacy data from a larger range of clinical NDM-1-
producing Enterobacteriaceae isolates, with additional compara-
tor agents, are needed to best characterize the potential clinical
utility of these regimens. In the present study, we sought to de-
scribe the in vivo efﬁcacy of human simulated doses of both high-
dose, prolonged-infusion and standard regimens of doripenem,
ertapenem, ceftazidime, aztreonam, and levoﬂoxacin against an
isogenic pair consisting of a wild-type and an NDM-1-producing
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strain and eight clinical NDM-1-producing isolates in a murine
thigh infection model.
MATERIALS AND METHODS
Antimicrobial test agents. Commercially available ertapenem (Invanz,
Merck & Co., Inc., Whitehouse Station, NJ), doripenem (Doribax; Jans-
sen Pharmaceuticals, Inc., Raritan, NJ), ceftazidime (Fortaz; GlaxoSmith-
Kline, Philadelphia, PA), aztreonam (Azactam; Bristol-Myers Squibb,
Princeton, NJ), and levoﬂoxacin (Sagent Pharmaceuticals, Schaumburg,
IL) were obtained from the pharmacy department at Hartford Hospital
for use in all in vivo experiments. Each drug was reconstituted according
to the manufacturer’s prescribing information and then further diluted in
normal saline to the concentrations required for dosing. Dosing solutions
were prepared just prior to each experiment, stored under refrigeration,
and discarded after 24 h.
Bacterial isolates. An isogenic pair consisting of a wild-type K. pneu-
moniae strain (KP 454) and an NDM-1-producing strain derived by con-
jugation and four clinical NDM-1-producing Enterobacteriaceae isolates
(EC 389, EC 393, KP 425, and KP 450) were provided by Patrice Nord-
mann,Hospital Bicêtre (LeKremlin-Bicêtre, France) (10). The ertapenem
and doripenem MICs for these isolates were determined via Etest (AB
bioMérieux, Solna, Sweden) according to the manufacturer’s instruc-
tions. The MICs of ceftazidime, aztreonam, and levoﬂoxacin for these
isolates were determined by brothmicrodilution consistent with the Clin-
ical and Laboratory Standards Institute (CLSI) methodology (12). Pseu-
domonas aeruginosaATCC27853was used as the quality control strain for
all three agents evaluated by broth microdilution. MIC determinations
were conducted in triplicate, and MICs are reported as modal values un-
less otherwise noted. Four additional clinical NDM-1-producing Entero-
bacteriaceae isolates (KP 476, KP 477, KP 478, and ECL 70) were kindly
provided by Christine Lascols, International Health Management Associ-
ates, Inc. (Schaumburg, IL) (13). The MICs of all ﬁve of the agents eval-
uated were determined by broth microdilution as outlined above. All of
the isolates were screened for KPC, OXA-48-like, VIM, IMP, and NDM
carbapenemases, as well for extended-spectrum -lactamases (TEM,
SHV, and CTX-M) and AmpC -lactamases (CMY, DHA, FOX, MOX,
ACC, and ACT), as previously described (13). Isolates were stored at
80°C in double-strength skimmilk (Remel, Lenexa, KS). Prior to each in
vivo experiment, isolates were subcultured twice onto Trypticase soy agar
with 5% sheep blood (BDBiosciences, Sparks,MD) and incubated at 35°C
for 18 to 24 h.
Immunocompetent-mouse thigh infection model. This study was
reviewed and approved by the Institutional Animal Care and Use Com-
mittee at Hartford Hospital, Hartford, CT. Pathogen-free ICR mice
weighing 20 to 22 g were acquired from Harlan Laboratories (Indianap-
olis, IN). All animals were maintained in accordance with the National
Research Council’s recommendations and were provided food and water
ad libitum. Three days prior to inoculation for in vivo experiments, an
intraperitoneal injection of uranyl nitrate (5 mg/kg) was given to produce
a predictable level of renal impairment in order to slow antibiotic clear-
ance (14). Two hours prior to the initiation of antimicrobial therapy, both
thighs of each animal were inoculated intramuscularly with 0.1 ml of an
inoculum solution containing the test isolate at 108 CFU/ml of normal
saline.
Neutropenic thigh infection model. The isogenic wild-type and
NDM-1-producing strains and two of the clinical NDM-1-producing iso-
lates were also evaluated in a neutropenic infection model for efﬁcacy
comparison. The mice used in the neutropenic-mouse model underwent
the same procedures as described for the immunocompetent-mouse
model and were also given intraperitoneal injections of cyclophospha-
mide (Baxter, Deerﬁeld, IL) at 100 and 150 mg/kg 1 and 4 days prior to
inoculation, respectively, to induce neutropenia (14). Furthermore, an
inoculum solution of 107 CFU/ml was used to produce thigh infection in
neutropenic mice.
In vivo efﬁcacy. For each isolate, groups of three mice were adminis-
tered a human simulated regimen of doripenem, ertapenem, ceftazidime,
aztreonam, or levoﬂoxacin beginning 2 h after inoculation. Humanized
regimens previously developed and validated by our group to simulate the
human pharmacodynamic proﬁle of 2 g of doripenem given intrave-
nously (i.v.) every 8 h as a 4-h infusion, 1 g of ertapenemgiven i.v. every 24
h, 2 g of ceftazidime given i.v. every 8 h as a 2-h infusion, 2 g of aztreonam
given i.v. every 6 h as a 1-h infusion, and 500 mg of levoﬂoxacin given
every 24 h were used throughout (15–19). Since in vivo efﬁcacy has been
demonstrated previously with high-dose, prolonged infusion of dorip-
enem, a standard doripenem dose of 500 mg given i.v. every 8 h was also
evaluated against the four isolates with the highest doripenemMICs in the
immunocompetent-mouse model and all of the isolates in the neutro-
penic-mouse model (20). Each dose within these regimens was adminis-
tered as a 0.2-ml subcutaneous injection, with dosing regimens repeated
when necessary to complete 24 h of therapy. Three control animals for
each isolate were given normal saline in the same volume, by the same
route, and at the same frequency as the most frequently administered
treatment regimen over 24 h. Groups of untreated control mice were
harvested at 0 h, while the control mice that received normal saline and all
of the treated mice were harvested at 24 h. Mice that failed to survive to 24
h were harvested at the time of expiration and were included in the ﬁnal
data analysis. Harvesting consisted of euthanization by CO2 exposure,
followed by cervical dislocation. Thighs were then removed from sacri-
ﬁced animals and homogenized individually in normal saline. Serial dilu-
tions of thigh homogenate were plated onto Trypticase soy agar with 5%
sheep blood for determination of bacterial density. For experiments con-
ducted in the neutropenic thigh infectionmodel, efﬁcacywas calculated as
the change in bacterial density (in log10 CFU) in treated mice after 24 h
from the starting bacterial densities in 0-h control animals. In order to
control for the effect of the host and associated variability of 0-h control
bacterial density between isolates, efﬁcacy in experiments conducted in
the immunocompetent-mousemodel was calculated as the change in bac-
terial density in treated mice after 24 h compared to that in the 24-h
immunocompetent control mice (10, 21). The efﬁcacy of human simu-
lated high-dose, prolonged infusion of doripenem and the standard regi-
men of ertapenem was evaluated previously for the isogenic pair, EC 389,
EC393, and KP 425 and has been included to provide a complete compar-
ison (10). The observed efﬁcacies of the two doripenem regimens and the
ertapenem regimen were compared for each isolate by one-way repeated-
measures analysis of variance. A P value of0.05 was deﬁned a priori as
statistically signiﬁcant.
RESULTS
Bacterial isolates. An isogenic pair consisting of wild-type K.
pneumoniae 454, the NDM-1-producing strain derived from it,
and a group of eight clinical NDM-1-producing Enterobacteria-
ceae isolates, were used. Phenotypic proﬁles for the ﬁve antimicro-
bials evaluated and the known genotypic proﬁles for all of the
isolates included in the efﬁcacy studies are described in Table 1
(10, 13). Brieﬂy, the wild-type strain (KP 454) was susceptible to
all ﬁve antibiotics tested, while the addition of NDM-1 to this
strain resulted in in vitro resistance to ceftazidime, ertapenem, and
doripenem according to current CLSI breakpoints. Most of the
clinical strains used coproduced a variety of other -lactamases
and were resistant to nearly all of the -lactam agents used in this
study. Furthermore, six of the eight clinical strains were also resis-
tant to levoﬂoxacin.
In vivo efﬁcacy. The isogenic pair and all eight clinical iso-
lates were evaluated in the immunocompetent-mouse model.
In these studies, the mean bacterial density ( the standard
deviation) in 0-h control mice was 6.82  0.32 log10 CFU per
thigh and was maintained at 6.82  1.23 log10 CFU per thigh
after 24 h. The efﬁcacy results of the immunocompetent-
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mouse studies are shown in Fig. 1. All ﬁve of the antimicrobials
tested achieved a1-log10 CFU reduction of the isogenic wild-
type and NDM-1-producing strains. Consistent with ceftazi-
dime MICs of128g/ml (ƒTMIC, 0%), levoﬂoxacin MICs of
64 g/ml (ƒTMIC, 10%), and levoﬂoxacin MICs of 0.5
g/ml (AUC/MIC ratio,88), none of these three agents pro-
duced consistent reductions in bacterial density across the
eight clinical isolates evaluated. However, the high-dose, pro-
longed doripenem infusion regimen and the ertapenem regi-
men both resulted in substantial bacterial reductions for all
TABLE 1 Phenotypic and genotypic proﬁles of Enterobacteriaceae isolates used in the in vivo efﬁcacy studies described here
Isolate Known -lactamase content (10, 13)
MIC (g/ml)a
DOR ETP CAZ ATM LEV
K. pneumoniae 454 None 0.03 0.012 0.25 0.25 0.06
K. pneumoniae 454
NDM-1 plasmid
NDM-1 4 16 128 2 0.125
E. coli 389 NDM-1, TEM-1, CTX-M-15 8 32 128 256 32
E. coli 393 NDM-1, CTX-M-15, TEM-1, OXA-1, OXA-2 4 32 128 256 32
K. pneumoniae 425 NDM-1, TEM-1, SHV-11, CTX-M-15, CMY-16, OXA-1, OXA-9, OXA-10 32 32 128 256 0.5
K. pneumoniae 450 NDM-1, SHV-11, SHV-28, TEM-1, CTX-M-15, OXA-1, OXA-9 32 32 128 256 16
K. pneumoniae 476 NDM-1 64 128 128 64 32
K. pneumoniae 477 NDM-1, SHV-2A, AmpC, DHA-1 64 128 128 128b 32
K. pneumoniae 478 NDM-1, CTX-M-15 64 128 128 256 32
E. cloacae 70 NDM-1 64 64 128 128 0.5
a DOR, doripenem; ETP, ertapenem; CAZ, ceftazidime; ATM, aztreonam; LEV, levoﬂoxacin.
b Median value reported in the absence of a mode.
FIG 1 Efﬁcacies of human simulated regimens of 500 mg of doripenem (DOR) given every 8 h and 2 g given every 8 h as a 4-h infusion (A), 1 g of ertapenem
(ETP) given every 24 h (B), 2 g of ceftazidime (CAZ) given i.v. every 8 h as a 2-h infusion (C), 2 g of aztreonam (ATM) given i.v. every 6 h as a 1-h infusion (D),
and 500 mg of levoﬂoxacin (LEV) given i.v. every 24 h (E) against a group of NDM-1-producing Enterobacteriaceae isolates (CLSI susceptibility breakpoints:
doripenem,1 g/ml; ertapenem,0.5 g/ml; ceftazidime,4 g/ml; aztreonam,4 g/ml; levoﬂoxacin,2 g/ml [45]) in an immunocompetent-mouse
thigh infection model. Error bars represent standard deviations. For isolates where both doripenem regimens were evaluated, the asterisks denote a statistically
signiﬁcantly greater observed efﬁcacy of 2 g of doripenemgiven every 8 h as a 4-h infusion than of 500mgof doripenemgiven every 8 h and 1 g of ertapenemgiven
every 24 h (P 0.05).
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eight clinical strains, even in the light of six of these isolates
having doripenem MICs of 32 g/ml (ƒTMIC, 0%) and all
eight isolates having ertapenem MICs of 32 g/ml (ƒTMIC,
0%). While doripenem efﬁcacy against the four isolates was
demonstrated with both regimens, with doripenem MICs of
64 g/ml, numerically greater reductions of all four of the
bacterial isolates evaluated were attained with the high-dose,
prolonged-infusion regimen than with the standard 500-mg
dose, and the difference was statistically signiﬁcant for two of
these isolates (Fig. 1A).
The isogenic wild-type and NDM-1-producing strains plus
twoof the clinicalNDM-1-producing strains (EC380 andKP425)
were also evaluated in a neutropenic-mousemodel in order to best
ascertain the efﬁcacy of the regimens evaluatedwithout the impact
of the host. In these studies, the mean bacterial density in 0-h
control mice ( the standard deviation) was 5.99  0.49 log10
CFU per thigh and increased to a mean of 9.10 0.51 log10 CFU
per thigh after 24 h. The results of the neutropenic studies are
depicted in Fig. 2. Similar trends in efﬁcacy with respect to phe-
notypic and pharmacodynamic proﬁles were noted between the
immunocompetent- and neutropenic-mouse studies.
DISCUSSION
The rate at which the metallo--lactamase NDM-1 has dissemi-
nated globally among members of the family Enterobacteriaceae is
alarming (2). Without antimicrobials with novel mechanisms of
action readily available, evaluation of the potential clinical utility
of existing agents for the treatment of infections caused by these
resistant pathogens is imperative. Since preliminary data on the in
vivo efﬁcacy of carbapenem regimens for NDM-1-producing or-
ganisms looked promising, we sought to corroborate these ﬁnd-
ings by using an expanded group of NDM-1-producing isolates
and including other comparator agents (ceftazidime, aztreonam,
and levoﬂoxacin) whose pharmacodynamic proﬁles have previ-
ously been well characterized in the same in vivo infection model.
In the present study, in vivo efﬁcacywas observedwith all of the
regimens tested against the wild-type K. pneumoniae strain, as
expected. Comparable efﬁcacies of levoﬂoxacin, aztreonam, and
high-dose, prolonged infusion of doripenem against the isogeni-
cally constructed NDM-1-producing strain were also observed, as
predicted on the basis of the pharmacodynamic targets required
for efﬁcacy of an AUC/MIC ratio of125, an ƒTMIC of50%,
FIG 2 Efﬁcacies of human simulated regimens of 500 mg of doripenem (DOR) given every 8 h and 2 g of doripenem given every 8 h as a 4-h infusion (A), 1 g
of ertapenem (ETP) given every 24 h (B), 2 g of ceftazidime (CAZ) given i.v. every 8 h as a 2-h infusion (C), 2 g of aztreonam (ATM) given i.v. every 6 h as a 1-h
infusion (D), and 500 mg of levoﬂoxacin (LEV) given i.v. every 24 h (E) against a group of NDM-1-producing Enterobacteriaceae isolates (CLSI susceptibility
breakpoints: doripenem, 1 g/ml; ertapenem, 0.5 g/ml; ceftazidime, 4 g/ml; aztreonam, 4 g/ml; levoﬂoxacin, 2 g/ml [45]) in a neutropenic-
mouse thigh infection model. Error bars represent standard deviations. The asterisks denote a statistically signiﬁcantly greater observed efﬁcacy of 2 g of
doripenem given every 8 h as a 4-h infusion than of 500 mg of doripenem given every 8 h and 1 g of ertapenem given every 24 h (P 0.05).
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and an ƒTMIC of 40%, respectively (22–24). However, ertap-
enem and ceftazidime also demonstrated efﬁcacy against the iso-
genic strain, even though the ƒTMIC achieved with these agents
for this strain was 0%.
Neither ceftazidime nor aztreonam nor levoﬂoxacin produced
reliable efﬁcacy across the eight clinical NDM-1-producing iso-
lates evaluated in the immunocompetent-mousemodel or the two
isolates that were also evaluated in the neutropenic-mouse model,
as anticipated on the basis of pharmacodynamic exposures of
these isolates that were achieved. Even though efﬁcacy of ceftazi-
dime against the isogenic NDM-1-producing strain was noted
when the ƒTMIC was 0%, minimal efﬁcacy against the eight clin-
ical strains with similar phenotypic proﬁles was seen, as antici-
pated, givenNDM-1’s efﬁcient hydrolysis ofmost cephalosporins,
coupled with the coproduction of additional -lactamases by the
clinical isolates (1). While variable efﬁcacy of levoﬂoxacin against
the two clinical strains was noted, with a MIC of 0.5g/ml, essen-
tially no activity against the other six strains was observed, with
MICs of 16 g/ml. These data were consistent with the previ-
ously published pharmacodynamic target for ﬂuoroquinolones
against Gram-negative pathogens of an AUC/MIC ratio of125,
as the AUC/MIC ratio was88 for these eight clinical strains (24).
A lack of consistent efﬁcacy was also noted with aztreonam across
the eight resistant clinical strains, consistent with a ƒTMIC of
10% for these isolates (18, 23). While aztreonam is not a sub-
strate for metallo--lactamase enzymes such as NDM-1, mono-
therapy is not a viable option for treating infections with NDM-
1-producing Enterobacteriaceae because of the high likelihood of
the coproduction of CTX-M- and CMY-type -lactamases, as ev-
idenced by our results with the clinical strains (1, 9).
Even though the requisite 40% ƒTMIC needed for efﬁcacy was
achieved in only two of the eight clinical isolates with doripenem
and in no isolates with ertapenem, bacterial reductions were
achieved with both agents against all of the clinical strains evalu-
ated in the immunocompetent- and neutropenic-mouse models
(22). Furthermore, 1-log10 CFU reductions of six of the eight
clinical strains were achieved with both the doripenem and ertap-
enem regimens in the immunocompetent-mouse model. Simi-
larly, reductions of the two isolates used in the neutropenic-
mouse model were also observed with these regimens. When the
doripenem regimens were compared directly, the high-dose, pro-
longed-infusion regimen of 2 g given every 8 h as a 4-h infusion
showed a slight enhancement in efﬁcacy over the standard regi-
men of 500 mg given every 8 h. The unanticipated activity of the
carbapenems against these resistant NDM-1-producing isolates
may be supported by the enzyme’s reduced hydrolytic efﬁciency
for carbapenems. In an enzyme kinetic study, NDM-1 exhibited
less efﬁcient hydrolysis of imipenem and meropenem than IMP-1
but was similar to that of VIM-2, which is known to hydrolyze
carbapenems more slowly than other metallo--lactamases (1,
25). Because of this variation in the hydrolytic efﬁciency of car-
bapenems among the various metallo--lactamases, the efﬁcacy
observed with carbapenems in the present study cannot be readily
extrapolated to strains that produce other metallo--lactamases
without additional in vivo evaluation against VIM- and IMP-pro-
ducing strains.
While a great majority of the published case reports focus
solely on the emergence and detection of NDM-1-producing
strains in patients from around the world, some also describe the
clinical course and treatment outcomes for these patients. It ap-
pears that a majority of the cases that include clinical outcomes
have predominantly been treated successfully, most often with
colistin- and/or amikacin-based regimens (26–39). It is likely that
this collection of largely positive case reports is a result of publi-
cation bias and should be interpreted cautiously, since a small
number of clinical failures with these same regimens have also
been reported (6–8, 40). Nonetheless, consistent with the in vivo
efﬁcacy of carbapenems demonstrated in this study, four case re-
ports have been published to date describing the successful treat-
ment of infections caused by NDM-1 producers with mero-
penem- or ertapenem-based regimens (41–44). The ﬁrst case was
a patient with urosepsis caused by an NDM-1-producing Esche-
richia coli strain susceptible to meropenem, imipenem, tigecy-
cline, colistin, and trimethoprim-sulfamethoxazole who success-
fully cleared the infection after an initial course of meropenem,
followed by trimethoprim-sulfamethoxazole (41). A second pa-
tient with prostatitis, pyelonephritis, and an NDM-1-producing
E. coli strain isolated from a clean-catch urine culture also dem-
onstrated clinical improvement and microbiologic clearance of
urine cultures with an ertapenem course of 2 g daily, followed by a
single dose of fosfomycin, despite the isolate’s resistance to ertap-
enem (42). Another patient who developed ventilator-associated
pneumonia, likely caused by NDM-1-producing Acinetobacter
baumannii, was treated with 7 days of meropenem and metroni-
dazole. While the initial isolate recovered from a bronchoalveolar
lavage sample and an oral cavity swab was resistant to mero-
penem, the patient recovered; however, it was unclear if this or-
ganism represented infection or colonization (43). A fourth pa-
tient treated for an abscess of the right iliac fossa also showed
clinical improvement after 2 weeks of meropenem. However, ad-
equate abscess drainage may have played a critical role in his re-
covery (44). While these clinical data are scarce and confounded
by combination regimens and other clinical variables, they do
appear to support the potential utility of carbapenems for treating
NDM-1-producing Enterobacteriaceae infections and the discor-
dance observed in this study between the phenotypic proﬁle and
in vivo efﬁcacy.
Consistent with phenotypic proﬁles and pharmacodynamic
targets, ceftazidime, aztreonam, and levoﬂoxacin did not show
consistent efﬁcacy against the NDM-1-producing strains evalu-
ated in this study, particularly in the absence of a functioning
immune system. Only the simulated carbapenem regimens in-
cluding standard and high-dose, prolonged infusion of dorip-
enem and ertapenem demonstrated efﬁcacy against these patho-
gens in both immunocompetent- and neutropenic-mouse thigh
infection models, even in the light of elevated MICs. While there
are currently new -lactamase inhibitors and other novel drug
targets in various phases of development, these data suggest that
carbapenem-based regimensmay represent a viable treatment op-
tion for infections caused by NDM-1-producing isolates in the
interim.
ACKNOWLEDGMENTS
This study was supported with internal funds from the Center for Anti-
Infective Research and Development, Hartford Hospital.
We acknowledge Amira Bhalodi, Shawn MacVane, Kevin Connors,
Debora Santini, Lindsay Tuttle, Jennifer Hull, Henry Christensen, Mary
Anne Banevicius, Lucinda Lamb, and PamTessier (Center for Anti-Infec-
tive Research&Development,HartfordHospital) for their assistancewith
the animal experimentation and Christina Sutherland and Pam Tessier
5
ht
tp
://
do
c.
re
ro
.c
h
for their assistance with MIC determinations. We thank Delphine Girlich
(Department of Bacteriology-Virology, Hospital Bicêtre, Le Kremlin-
Bicêtre, France) for determining MICs and constructing the isogenic
strains. We also thank Christine Lascols and Meredith Hackel (Interna-
tional Health Management Associates, Inc., Schaumburg, IL) for provid-
ing clinical NDM-1-producing strains.
REFERENCES
1. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR.
2009.Characterizationof anewmetallo-beta-lactamase gene,blaNDM-1, anda
novel erythromycin esterase gene carried on a unique genetic structure in
Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents
Chemother. 53:5046–5054. http://dx.doi.org/10.1128/AAC.00774-09.
2. Shakil S, Azhar EI, Tabrez S, Kamal MA, Jabir NR, Abuzenadah AM,
Damanhouri GA, AlamQ. 2011. NewDelhimetallo--lactamase (NDM-1):
an update. J. Chemother. 23:263–265. http://www.researchgate.net
/publication/51724850_New_Delhi_metallo-lactamase_(NDM-1)_an
_update.
3. Centers for Disease Control and Prevention (CDC). 2010. Detection of
Enterobacteriaceae isolates carrying metallo-beta-lactamase—United
States, 2010. MMWR Morb. Mortal. Wkly. Rep. 59:750. http://www.cdc
.gov/mmwr/preview/mmwrhtml/mm5924a5.htm.
4. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F,
Balakrishnan R, Uma C, Doumith M, Giske CG, Irfan S, Krishnan P,
Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A,
Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E,
Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W,
Livermore DM, Woodford N. 2010. Emergence of a new antibiotic resis-
tance mechanism in India, Pakistan, and the UK: a molecular, biological,
and epidemiological study. Lancet Infect. Dis. 10:597–602. http://dx.doi
.org/10.1016/S1473-3099(10)70143-2.
5. Albur M, Noel A, Bowker K, MacGowan A. 2012. Bactericidal activity of
multiple combinations of tigecycline and colistin against NDM-1-
producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56:3441–
3443. http://dx.doi.org/10.1128/AAC.05682-11.
6. Poirel L, Ozdamar M, Ocampo-Sosa AA, Turkoglu S, Ozer UG, Nor-
dmann P. 2012. NDM-1-producing Klebsiella pneumoniae now in Tur-
key. Antimicrob. Agents Chemother. 56:2784–2785. http://dx.doi.org/10
.1128/AAC.00150-12.
7. Chan HLW, Poon LM, Chan SG, Teo JWP. 2011. The perils of medical
tourism: NDM-1 positive Escherichia coli causing febrile neutropenia in a
medical tourist. Singapore Med. J. 52:299–302. http://smj.sma.org.sg/52
04/5204cr1.pdf.
8. Mulvey MR, Grant JM, Plewes K, Roscoe D, Boyd DA. 2011. New Delhi
metallo--lactamase in Klebsiella pneumoniae and Escherichia coli, Can-
ada. Emerg. Infect. Dis. 17:103–106. http://dx.doi.org/10.3201/eid1701
.101358.
9. Bush K. 2013. The ABCD’s of -lactamase nomenclature. J. Infect. Che-
mother. 19:549–559. http://dx.doi.org/10.1007/s10156-013-0640-7.
10. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2013. Efﬁcacy
of humanized carbapenem exposures against New Delhi metallo-beta-
lactamase (NDM-1) producing Enterobacteriaceae in a murine infection
model. Antimicrob. Agents Chemother. 57:3936–3940. http://dx.doi.org
/10.1128/AAC.00708-13.
11. Wiskirchen DE, Crandon JL, Nicolau DP. 2013. Impact of various
conditions on the efﬁcacy of dual carbapenem therapy against KPC-
producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 41:582–585.
http://dx.doi.org/10.1016/j.ijantimicag.2013.02.015.
12. Clinical Laboratory Standards Institute. 2012. Methods for dilution an-
timicrobial susceptibility tests for bacteria that grow aerobically; approved
standard, 9th ed CLSI publication M07–A9. Clinical Laboratory Standard
Institute, Wayne, PA.
13. Lascols C, Peirano G, Hackel M, Laupland KB, Pitout JD. 2013. Sur-
veillance and molecular epidemiology of Klebsiella pneumoniae isolates
that produce carbapenemases: ﬁrst report of OXA-48-like enzymes in
North America. Antimicrob. Agents Chemother. 57:130–136. http://dx
.doi.org/10.1128/AAC.01686-12.
14. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicil-
lin-clavulanate against Streptococcus pneumoniae: application to break-
point determinations. Antimicrob. Agents Chemother. 42:2375–2379.
15. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. 2007. Bactericidal
activities of meropenem and ertapenem against extended-spectrum--
lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neu-
tropenic mouse thigh model. Antimicrob. Agents Chemother. 51:1481–
1486. http://dx.doi.org/10.1128/AAC.00752-06.
16. Crandon JL, Bulik CC, Nicolau DP. 2009. In vivo efﬁcacy of 1- and
2-gramhuman simulated prolonged infusions of doripenem against Pseu-
domonas aeruginosa. Antimicrob. Agents Chemother. 53:4352–4356.
http://dx.doi.org/10.1128/AAC.00282-09.
17. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW,
Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efﬁca-
cies of human simulated doses of ceftazidime and ceftazidime-avibactam
against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:
6137–6146. http://dx.doi.org/10.1128/AAC.00851-12.
18. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam
and aztreonam-avibactam to evaluate activity against challenging gram-
negative organisms, including metallo--lactamase producers. Antimi-
crob. Agents Chemother. 57:3299–3306. http://dx.doi.org/10.1128/AAC
.01989-12.
19. Onyeji CO, Bui KQ, Owens RC, Nicolau SP, Quintiliani R, Nightingale
CH. 1999. Comparative efﬁcacies of levoﬂoxacin and ciproﬂoxacin
against Streptococcus pneumoniae in a mouse model of experimental
septicaemia. Int. J. Antimicrob. Agents 12:107–114. http://dx.doi.org/10
.1016/S0924-8579(98)00087-9.
20. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic
proﬁling of doripenem against Pseudomonas aeruginosa by simulating hu-
man exposures. Antimicrob. Agents Chemother. 52:2497–2502. http://dx
.doi.org/10.1128/AAC.01252-07.
21. Keel RA, Crandon JL, Nicolau DP. 2011. Efﬁcacy of human simulated
exposuresof ceftarolineadministeredat600milligramsevery12hoursagainst
phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents
Chemother. 55:4028–4032. http://dx.doi.org/10.1128/AAC.00372-11.
22. Turnidge JD. 1998. The pharmacodynamics of beta-lactams. Clin. Infect.
Dis. 27:10–22. http://dx.doi.org/10.1086/514622.
23. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical
applications to the use of -lactams, glycopeptides, and linezolid. Infect.
Dis. Clin. North Am. 17:479–501. http://dx.doi.org/10.1016/S0891-5520
(03)00065-5.
24. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ.
1993. Pharmacodynamics of intravenous ciproﬂoxacin in seriously ill pa-
tients. Antimicrob. Agents Chemother. 37:1073–1081. http://dx.doi.org
/10.1128/AAC.37.5.1073.
25. Queenan AM, Shang W, Flamm R, Bush K. 2010. Hydrolysis and
inhibition proﬁles of -lactamases from molecular classes A to D with
doripenem, imipenem, andmeropenem. Antimicrob. Agents Chemother.
54:565–569. http://dx.doi.org/10.1128/AAC.01004-09.
26. Darley E, Weeks J, Jones L, Daniel V, Wootton M, MacGowan A, Walsh
T. 2012. NDM-1 polymicrobial infections including Vibrio cholera. Lancet
380:1358. http://dx.doi.org/10.1016/S0140-6736(12)60911-8.
27. Tsang KY, Luk S, Lo JY, Tsang TY, Lai ST, Hg TK. 2012. Hong Kong
experiences the ‘Ultimate superbug’: NDM-1 Enterobacteriaceae. Hong
Kong Med. J. 18:439–441. http://www.hkmj.org/abstracts/v18n5/439
.htm.
28. Flateau C, Janvier F, Delacour H, Males S, Ficko C, Andriamanantena
D, Jeannot K, Merens A, Rapp C. 2012. Recurrent pyelonephritis due to
NDM-1 metallo-beta-lactamase producing Pseudomonas aeruginosa in a
patient returning from Serbia, France, 2012. Euro Surveill. 17:pii	20311.
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId	20311.
29. Mochon AB, Garner OB, Hindler JA, Krogstad P, Ward KW, Lewinski
MA, Rasheed JK, Anderson KF, Limbago B, Humphries RM. 2011. New
Delhi metallo--lactamase (NDM-1)-producing Klebsiella pneumoniae:
case report and laboratory detection strategies. J. Clin. Microbiol. 49:
1667–1670. http://dx.doi.org/10.1128/JCM.00183-11.
30. Roy S, Viswanathan R, Singh AK, Das P, Basu S. 2011. Sepsis in neonates
due to imipenem-resistant Klebsiella pneumoniae producing NDM-1 in
India. J. Antimicrob. Chemother. 66:1411–1413. http://dx.doi.org/10
.1093/jac/dkr068.
31. Stone NR, Woodford N, Livermore DM, Howard J, Pike R, Mushtaq S,
Perry C, Hopkins S. 2011. Breakthrough bacteraemia due to tigecycline-
resistant Escherichia coli with New Delhi metallo--lactamase (NDM)-1
successfully treated with colistin in a patient with calciphylaxis. J. Antimi-
crob. Chemother. 66:2677–2678. http://dx.doi.org/10.1093/jac/dkr337.
32. Chien JM, Koh TH, Chan KS, Chuah TH, Tan TT. 2012. Successful
treatment of NDM-1 Klebsiella pneumoniae bacteraemia in a neutropenic
6
ht
tp
://
do
c.
re
ro
.c
h
patient. Scand. J. Infect. Dis. 44:312–314. http://dx.doi.org/10.3109
/00365548.2011.633549.
33. Pasteran F, Albornoz E, Faccone D, Gomez S, Valenzuela C, Morales
M, Estrada P, Valenzuela L, Matheu J, Guerriero L, Arbizu E, Calderon
Y, Ramon-Pardo P, Corso A. 2012. Emergence of NDM-1-producing
Klebsiella pneumoniae in Guatemala. J. Antimicrob. Chemother. 67:1795–
1797. http://dx.doi.org/10.1093/jac/dks101.
34. Hu H, Hu Y, Pan Y, Liang H, Wang H, Wang X, Hao Q., Yang X, Yang
X, Xiao X, Luan C, Yang Y, Cui Y, Yang Rk, Gao G, Song Y, Zhu B.
2012. Novel plasmid and its variant harboring both a bla(NDM-1) gene
and type IV secretion system in clinical isolates of Acinetobacter lwofﬁi.
Antimicrob. Agents Chemother. 56:1698–1702. http://dx.doi.org/10
.1128/AAC.06199-11.
35. Lowman W, Sriruttan C, Nana T, Bosman N, Duse A, Venturas J, Clay
C, Coetzee J. 2011. NDM-1 has arrived: ﬁrst report of a carbapenem
resistance mechanism in South Africa. S. Afr. Med. J. 101:873–875. http:
//www.scielo.org.za/scielo.php?pid	S0256-95742011001200015&script
	sci_arttext.
36. Chihara S, Okuzumi K, Yamamoto Y, Oikawa S, Hishinuma A. 2011.
First case of New Delhi metallo--lactamase 1-producing Escherichia coli
infection in Japan.Clin. Infect.Dis. 52:153–154. http://dx.doi.org/10.1093
/cid/ciq054.
37. Khajuria A, Praharaj AK, Grover N, Kumar M. 2013. First report of
blaNDM-1 in Raoultella ornithinolytica. Antimicrob. Agents Chemother.
57:1092–1093. http://dx.doi.org/10.1128/AAC.02147-12.
38. Sidjabat H, Nimmo GR, Walsh TR, Binotto E, Htin A, Hayashi Y, Li J,
Nation RL, George N, Paterson DL. 2011. Carbapenem resistance in
Klebsiella pneumoniae due to the New Delhi metallo--lactamase. Clin.
Infect. Dis. 52:481–484. http://dx.doi.org/10.1093/cid/ciq178.
39. Hoang TH, Wertheim H, Minh NB, Duong TN, Anh DD, Phuong TT,
Son TH, Izumiya H, Ohnishi M, Shibayama K, Hien NT. 2013. Car-
bapenem-resistant Escherichia coli and Klebsiella pneumoniae strains con-
taining New Delhi metallo-beta-lactamase isolated from two patients in
Vietnam. J. Clin. Microbiol. 51:373–374. http://dx.doi.org/10.1128/JCM
.02322-12.
40. Poirel L, Benouda A, Hays C, Nordmann P. 2011. Emergence of NDM-
1-producing Klebsiella pneumoniae in Morocco. J. Antimicrob. Che-
mother. 66:2781–2783. http://dx.doi.org/10.1093/jac/dkr384.
41. Samuelsen O, Thilesen CM, Heggelund L, Vada AN, Kummel A,
Sundsfjord A. 2011. Identiﬁcation of NDM-1-producing Enterobacteri-
aceae in Norway. J. Antimicrob. Chemother. 66:670–683. http://dx.doi
.org/10.1093/jac/dkq483.
42. Peirano G, Ahmed-Bentley J, Woodford N, Pitout J. 2011. New Delhi
metallo--lactamase from traveler returning to Canada. Emerg. Infect.
Dis. 17:242–244. http://dx.doi.org/10.3201/eid1702.101313.
43. Hrabak J, Stolbova M, Studentova V, Fridrichova M, Chudackova E,
Zemlickova H. 2012. NDM-1 producing Acinetobacter baumannii iso-
lated from a patient repatriated to the Czech Republic from Egypt, July
2011. Euro Surveill. 17:pii	20085. http://www.eurosurveillance.org
/ViewArticle.aspx?ArticleId	20085.
44. Oteo J, Domingo-Garcia D, Fernandez-Romero S, Saez D, Guiu A,
Cuevas O, Lopez-Brea M, Campos J. 2012. Abdominal abscess due to
NDM-1-producing Klebsiella pneumoniae in Spain. J. Med. Microbiol.
61:864–867. http://dx.doi.org/10.1099/jmm.0.043190-0.
45. Clinical and Laboratory Standards Institute. 2013. Performance stan-
dards for antimicrobial susceptibility testing; 23rd informational supple-
ment. CLSI M100-S23. Clinical and Laboratory Standards Institute,
Wayne, PA.
7
ht
tp
://
do
c.
re
ro
.c
h
